ASCENTAGE PHARMA GROUP Grants Restricted Share Units and Stock Options

Stock News04-20

ASCENTAGE PHARMA GROUP (06855) has announced that as of the date of this announcement, the company has granted 696,300 restricted share units under the 2022 Restricted Share Unit Plan to three selected individuals. These awards are equivalent to 696,300 shares. The grants include 393,800 restricted share units awarded to Dr. Yang Dajun, the company's Executive Director and CEO; 283,900 restricted share units awarded to Dr. Zhai Yifan, the company's Chief Medical Officer and a major shareholder; and 18,600 restricted share units awarded to one senior management member.

Additionally, as of the announcement date, the company has granted 513,200 stock options under the Post-IPO Share Option Scheme to Dr. Yang and Dr. Zhai. These options grant the holders the right to subscribe for a total of 513,200 ordinary shares of the company upon exercise. The grant is subject to acceptance by Dr. Yang and Dr. Zhai. Specifically, 298,200 stock options were granted to Dr. Yang, and 215,000 stock options were granted to Dr. Zhai.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1162386747?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-20 22:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1162386747","market":"fut","top_or_hot":-1,"title":"ASCENTAGE PHARMA GROUP Grants Restricted Share Units and Stock Options","media":"Stock News","content":"<p>ASCENTAGE PHARMA GROUP (06855) has announced that as of the date of this announcement, the company has granted 696,300 restricted share units under the 2022 Restricted Share Unit Plan to three selected individuals. These awards are equivalent to 696,300 shares. The grants include 393,800 restricted share units awarded to Dr. Yang Dajun, the company's Executive Director and CEO; 283,900 restricted share units awarded to Dr. Zhai Yifan, the company's Chief Medical Officer and a major shareholder; and 18,600 restricted share units awarded to one senior management member.</p>\n<p>Additionally, as of the announcement date, the company has granted 513,200 stock options under the Post-IPO Share Option Scheme to Dr. Yang and Dr. Zhai. These options grant the holders the right to subscribe for a total of 513,200 ordinary shares of the company upon exercise. The grant is subject to acceptance by Dr. Yang and Dr. Zhai. Specifically, 298,200 stock options were granted to Dr. Yang, and 215,000 stock options were granted to Dr. Zhai.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ASCENTAGE PHARMA GROUP Grants Restricted Share Units and Stock Options</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nASCENTAGE PHARMA GROUP Grants Restricted Share Units and Stock Options\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-04-20 22:48</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>ASCENTAGE PHARMA GROUP (06855) has announced that as of the date of this announcement, the company has granted 696,300 restricted share units under the 2022 Restricted Share Unit Plan to three selected individuals. These awards are equivalent to 696,300 shares. The grants include 393,800 restricted share units awarded to Dr. Yang Dajun, the company's Executive Director and CEO; 283,900 restricted share units awarded to Dr. Zhai Yifan, the company's Chief Medical Officer and a major shareholder; and 18,600 restricted share units awarded to one senior management member.</p>\n<p>Additionally, as of the announcement date, the company has granted 513,200 stock options under the Post-IPO Share Option Scheme to Dr. Yang and Dr. Zhai. These options grant the holders the right to subscribe for a total of 513,200 ordinary shares of the company upon exercise. The grant is subject to acceptance by Dr. Yang and Dr. Zhai. Specifically, 298,200 stock options were granted to Dr. Yang, and 215,000 stock options were granted to Dr. Zhai.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"","article_id":"1162386747","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1162386747","pubTimestamp":1776696533,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"ASCENTAGE PHARMA GROUP (06855) has announced that as of the date of this announcement, the company has granted 696,300 restricted share units under the 2022 Restricted Share Unit Plan to three...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1161":"生物科技","BK1574":"生物医药B类股","BK4139":"生物科技","AAPG":"亚盛医药","06855":"亚盛医药-B"},"translate_title":"亚盛医药集团授出限制性股份单位及购股权","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06855":1,"AAPG":1},"content_text":"ASCENTAGE PHARMA GROUP (06855) has announced that as of the date of this announcement, the company has granted 696,300 restricted share units under the 2022 Restricted Share Unit Plan to three selected individuals. These awards are equivalent to 696,300 shares. The grants include 393,800 restricted share units awarded to Dr. Yang Dajun, the company's Executive Director and CEO; 283,900 restricted share units awarded to Dr. Zhai Yifan, the company's Chief Medical Officer and a major shareholder; and 18,600 restricted share units awarded to one senior management member.\nAdditionally, as of the announcement date, the company has granted 513,200 stock options under the Post-IPO Share Option Scheme to Dr. Yang and Dr. Zhai. These options grant the holders the right to subscribe for a total of 513,200 ordinary shares of the company upon exercise. The grant is subject to acceptance by Dr. Yang and Dr. Zhai. Specifically, 298,200 stock options were granted to Dr. Yang, and 215,000 stock options were granted to Dr. Zhai.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"shareholding","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1162386747","isCrawlerRequest":true}